WallStSmart
EDSA

Edesa Biotech Inc

NASDAQ: EDSA · HEALTHCARE · BIOTECHNOLOGY

$15.24
-22.99% today

Updated 2026-06-05

Market cap
$48.55M
P/E ratio
P/S ratio
130,462.29x
EPS (TTM)
$-1.31
Dividend yield
52W range
$1 – $20
Volume
0.6M

Edesa Biotech Inc (EDSA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-96.40%
ROA
-47.70%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2009$-73917.00
2010$854837.00$-589971.0054.83%-124.63%-69.02%
2011$697187.00$-7.09M-44.74%-1,018.37%-1,016.39%
2012$286054.00$-5.20M-52.56%-2,280.23%-1,816.68%
2013$545469.00$-14.89M-5.69%-674.37%-2,729.12%
2014$372132.00$-8.44M-104.30%-1,536.69%-2,267.88%
2015$758689.00$-2.84M-10.75%-571.85%-374.73%
2016$1.27M$-5.03M11.31%-385.97%-395.23%
2017$228287.00$-5.03M-134.11%-2,288.59%-2,203.65%
2018$211849.00$-5.04M-110.21%-2,397.11%-2,378.56%
2019$410870.00$-2.72M75.35%-689.30%-662.33%
2020$328801.00$-6.36M94.65%-1,946.72%-1,935.59%
2021$500.00$-13.34M-23,757.60%-4,736,266.40%-2,668,630.00%
2022$0.00$-17.55M
2023$0.00$-8.37M
2024$0.00$-6.17M
2025$0.00$-7.19M

Frequently asked questions

What is Edesa Biotech Inc's revenue?

Edesa Biotech Inc's trailing twelve-month revenue is $500.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does EDSA generate?

EDSA produced $-7.32M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is EDSA's balance sheet healthy?

EDSA holds $10.79M in cash and equivalents against — in long-term debt, on $12.45M of shareholder equity. That debt is best read against the cash flow the business throws off each year.